Latest News

ECLS trial demonstrates potential of blood test for early lung cancer detection

Oncimmune Holdings plc, a leading global immunodiagnostics group, welcomes the presentation of data today by Professor Frank Sullivan (Chief Investigator on the ECLS trial) which has demonstrated the potential of Oncimmune’s EarlyCDT Lung test to reduce the incidence of patients with late-stage lung cancer at diagnosis, compared with standard clinical diagnosis.

Source link

Related posts

How doctors convinced the world the planet was worth fighting for


Early plans can improve quality of life for hospice patients


Half of U.S. kids with a mental health disorder don't get treatment


This website uses cookies to improve your experience. We'll assume you're ok with this, but you can opt-out if you wish. Accept Read More

Privacy & Cookies Policy